Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts

Disseldorp, Jeroen van; Lambalk, Cornelis B.; Kwee, Janet; Looman, Caspar W.N.; Eijkemans, Marinus J.C.; Fauser, Bart C.J.M.; Broekmans, Frank J.

doi:10.1093/humrep/dep366

Cited by 313 publications

(222 citation statements)

References 41 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…van Disseldorp et al [19] compared the AFC with the AMH as to both their inter-cycle variability across four subsequent cycles and their stability across a full cycle in 77 women undergoing intrauterine insemination. They demonstrated that AMH provided less intra-individual fluctuation than the AFC both within and between cycles.…”

Section: Discussionmentioning

confidence: 99%

Serum anti‐Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

Şahmay

Çetin

Öçal

et al. 2010

Reprod Medicine & Biology

View full text Add to dashboard Cite

Purpose To evaluate the clinical value of day 3 serum anti-Müllerian hormone (AMH) compared with day 3 serum follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG) day estradiol (E2) levels and antral follicle count (AFC) in the prediction of poor ovarian response in controlled ovarian hyperstimulation (COH). Methods AMH, FSH and AFC on day 3 as well as hCG day E2 levels were determined in 164 subjects. Receiver operating curve analyses and area under curves (AUC) of the study parameters were performed. Predictive values of the levels of day 3 AMH, FSH, AFC, and hCG day E2 as clinical parameters of ovarian response to COH were studied. Results Thirty-eight women were defined as poor responders. The day 3 AMH and hCG day E2 levels and AFC of normal responders were significantly higher than those of the poor responders. In predicting poor response, the AUC of day 3 AMH level was significantly higher than that of day 3 FSH level but was similar to the hCG day E2 level. Day 3 AMH, FSH and hCG day E2 levels and AFC were found to predict a poor response. Day 3 AMH and hCG day E2 levels were more predictive compared with day 3 FSH level and AFC. The cut-off level of AMH was B2 with a sensitivity of 78.9% and a specificity of 73.8%. Conclusion Day 3 AMH has the ability to predict a poor response to COH and it is more predictive than day 3 FSH and AFC.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum anti‐Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

Şahmay

Çetin

Öçal

et al. 2010

Reprod Medicine & Biology

View full text Add to dashboard Cite

show abstract

“…Given that AMH represents the pool of oocytes remaining in the ovary, as a metric, it results in both consistent inter-and intra-menstrual cycle measurements [9]. Numerous studies have attempted to establish the efficacy of AMH in the fertility evaluation and treatment with measures of sensitivity, specificity, and predictive values.…”

Section: Introductionmentioning

confidence: 99%

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Tobler

Shoham

Christianson

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of this study is to assess how anti-mullerian hormone (AMH) is used worldwide to test ovarian reserve and guide in vitro fertilization (IVF) cycle management. Methods An internet-based survey was sent electronically to registered IVF providers within the IVF-Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of AMH. The questionnaire was completed online through the IVF-Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical IVF center. Results are reported as the proportion of IVF cycles represented by a particular answer choice. Results Survey responses were completed from 796 globally distributed IVF clinics, representing 593,200 IVF cycles worldwide. Sixty percent of the respondent-IVF cycles reported to use AMH as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that AMH results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. Conclusions AMH is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of IVF providers.

show abstract

“…The clinical significance of AMH determination was first proven in assisted reproduction, as AMH levels reflect the ovarian reserve potential with high accuracy (9)(10)(11)(12). There is also a strong correlation basal AMH level and the number of retrieved oocytes (10,12).…”

Section: Assisted Reproductionmentioning

confidence: 99%

Anti-Müllerian Hormone (Amh) in Gynecological Endocrinology

2017

ARC Journal of Gynecology and Obstetrics

View full text Add to dashboard Cite

Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts

Abstract: Serum AMH demonstrated less individual intra- and inter-cycle variation than AFCs and may therefore be considered a more reliable and robust means of assessing ovarian reserve in subfertile women.

Cited by 313 publications

References 41 publications

Serum anti‐Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

Serum anti‐Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Anti-Müllerian Hormone (Amh) in Gynecological Endocrinology

Contact Info

Product

Resources

About